Witnesses for the hearing are:
Panel I
- The Honorable Howard A. Shelanski, Administrator, Office of Information and Regulatory Affairs
Panel II
- Dr. Douglas Holtz-Eakin, President, American Action Forum
Jul 27th
From: The White House
by Tony Scott, Howard Shelanski, Anne Rung, Marc Groman
Today the Office of Management and Budget (OMB) is releasing an update to the Federal Government’s governing document for the management of Federal information resources: Circular A-130, Managing Information as a Strategic Resource.
Jul 14th
The Independent Republic a newsletter we were not acquainted with until it published this article on Arctic Drilling suggests that it provides unbiased information to its readers.
CRE merely made a comment on the aforementioned post calling to the attention of its readers a letter (Pritzker Letter June 16 i ) CRE sent to Secretary Pritzker. The moderator of the website decided not to publish the CRE letter.
Unlike the “Independent” Republic, CRE allows all readers with views that may be different from those of CRE to post on its website; thus the reason it has a substantial federal readership.
The Independent Republic states:
Jul 12th
From: The Hill
Rep. Tom Marino (R-Pa.) grilled President Obama’s top regulatory official Wednesday on what consequences there will be for federal agencies that try to rush through last-minute rules in the waning hours of the Obama administration.
Howard Shelanski, administrator of the Office of Information and Regulatory Affairs, issued a memo back in December advising the agencies to finish their highest priority rule-makings this summer to avoid a burst of “midnight regulations” before Obama leaves office.
Jul 7th
OIRA 2015 Report to Congress on the Benefits and Costs of Federal Regulations and Agency Compliance with the Unfunded Mandates Reform Act contains an extensive discussion of the Data Quality Act. OIRA’s Report to Congress is thus a major improvement over the draft report which did not discuss the DQA. In addition to reporting on Requests for Correction and litigation seeking judicial review of agency DQA decisions, the OIRA Report emphasizes the Administration’s “Continuing Commitment to Information Quality” particularly with respect to science data.
Jul 6th
From: House Judiciary Committee
Witnesses for the hearing are:
Panel I
Panel II
Jul 1st
From: The White House
***
Creation of a New Program to Accelerate Cancer Product Regulatory Review: The Food and Drug Administration (FDA) is excited to announce the hiring of Dr. Richard Pazdur as Acting Director of its new Oncology Center of Excellence (OCE). The OCE will unite cancer product regulatory review to enhance coordination and leverage the combined skills and clinical expertise across FDA centers. Under the Cancer Moonshot, the Acting Director is charged with accelerating the establishment of a program that brings together oncologists across the FDA in an effort to expedite the development of novel cancer-related drugs, biologics, and devices and support an integrated approach to tackling this devastating disease.